Patents by Inventor Mohammed El-Azami El-Idrissi

Mohammed El-Azami El-Idrissi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 10004794
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 26, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
    Publication number: 20160375119
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 29, 2016
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 9370564
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: June 21, 2016
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
    Publication number: 20120214206
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: June 27, 2011
    Publication date: August 23, 2012
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cécile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Modified adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
    Patent number: 7906123
    Abstract: The invention relates to modified Bordetella adenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection against Bordetella infection. The invention also relates to specific fragments of Bordetella adenylate cyclase comprising the CD11b/CD18 interaction domain and their use, especially for targeting a molecule of interest to CD11b expressing cells.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: March 15, 2011
    Assignees: Institut Pasteur, Centre National de la Recherche Scientique
    Inventors: Claude Leclerc, Mohammed El-Azami El-Idrissi, Daniel Ladant, Cécile Bauche, Peter Sebo, Jirina Loucka, Radim Osicka
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20050238637
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions, and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: April 5, 2005
    Publication date: October 27, 2005
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20040001867
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 1, 2004
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi